How Do Clinicians Evaluate Tysabri-Related PML Concerns?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Education to Occupational and Patient Safety

If you or a loved one is taking Tysabri and experiencing new neurological symptoms like confusion, vision changes, or weakness, you may be worried about progressive multifocal leukoencephalopathy (PML). Decades of pharmacovigilance have established that early detection is critical for improving outcomes. This page explains how clinicians evaluate the possibility of PML, from initial symptom recognition to confirmatory testing.

Bridging to Tysabri and PML Risk

Building on the broader context of occupational and patient safety, this section focuses specifically on Tysabri (natalizumab), a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Virginia who have developed PML after Tysabri treatment, understanding the medical evidence, risk factors, and legal considerations—including the statute of limitations—is essential. The prescribing information for Tysabri includes a boxed warning stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Medical Evidence and Risk Factors for PML

Three primary risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinically, PML presents with progressive neurological deficits such as weakness, visual changes, cognitive decline, and coordination difficulties. Diagnosis typically involves MRI imaging and detection of JC virus DNA in cerebrospinal fluid. The label emphasizes that healthcare professionals should "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and that "TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these precautions, PML can still occur, and outcomes are often poor. The mechanistic link between Tysabri and PML involves the drug's action as an alpha-4 integrin antagonist, which inhibits lymphocyte migration into the central nervous system. This immunosuppressive effect can allow reactivation of latent JC virus, leading to PML. The label notes that PML "typically only occurs in patients who are immunocompromised" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of this risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations and Statute of Limitations in Virginia

From a risk perspective, the adequacy of warnings is a central issue. The boxed warning and prescribing information clearly state the PML risk and the need for monitoring. However, patients and their families may question whether these warnings were sufficiently communicated or understood before treatment. For those affected, settlement-related considerations often involve evaluating the timeline between exposure and documented harm. PML can develop months to years after starting Tysabri, and the label reports cases with onset ranging from a few months to several years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period is critical for legal claims, as it affects when the injury is discovered. In Virginia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the discovery date may be when symptoms first appeared or when a formal diagnosis was made. Given the severity of PML, early diagnosis is challenging, and many patients may not recognize symptoms until significant neurological damage has occurred. Therefore, it is important for affected individuals to document the timeline of Tysabri treatment, onset of symptoms, and diagnosis. Settlements for Tysabri-related PML cases have been reported in multidistrict litigation, with amounts varying based on factors such as the extent of disability, medical expenses, and loss of earning capacity. Virginia residents pursuing claims should consult with an attorney experienced in pharmaceutical litigation to assess their specific circumstances and ensure compliance with the statute of limitations. In summary, Tysabri carries a known risk of PML, with identifiable risk factors and a clear mechanistic pathway. For Virginia patients who have developed PML, the adequacy of warnings and the timeline of harm are key considerations in any potential settlement. Legal action must be initiated within the applicable statute of limitations, typically two years from discovery of the injury.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Virginia?

In Virginia, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML, the discovery date may be when symptoms first appeared or when a formal diagnosis was made. It is crucial to document the timeline of Tysabri treatment, symptom onset, and diagnosis to ensure compliance with this deadline.

What are the primary risk factors for developing PML while on Tysabri?

The three primary risk factors for PML in Tysabri patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors should be weighed against expected benefits when initiating or continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.